you, everyone. George, afternoon, and good Thank
data with which ODYSSEY advance pleased III CLS-AX month, trial Phase our the We for into exceeded extremely result, which we development. are needed last expectations to the reported
we from trial. were were X ODYSSEY objectives key the looking There for
This administered at CLS-AX. of with safety. of First, showed safety and was the the X least patients maintained repeat the well almost tolerated dosing important were We all CLS-AX profile as drug. especially doses of was positive a
events, Phase including no no serious endometritis trial adverse treatment-related had no IIb vasculitis. our retinal and Importantly,
thickness, were with vision anatomical saw to weeks and X independent also We acuity weeks, to we We XX. corrected over XX efficacy. reading control demonstrate as provide Second, from subfield both that best CST stable within were XX by stable at reduced measurement XX able center. week and able fluctuations visual week maintain baseline confirmed and over BCVA central letters of CLS-AX
an to the with up reduction not initial participants XX% CLS-AX show XX% duration We third, months, any frequency X of And X approximately of CLS-AX, after the able XX% additional reduction and and of dose require X to injection to months. treatment months, up were in burden. of up treatment XX% to
Wet chronic disease. AMD is a
patient's life the numerous Over to vision given injections stabilize will the time, they disease. be and maintain
the as treatment. ability a of was the a are We maintenance developing trial. administer ODYSSEY dose component fact to of we multiple that CLS-AX demonstrated critical CLS-AX And the
new conditions, received easily needs entrant for physician that a We flexible current every order in physicians the want only adopted input from on be Based agent therapy meaningful, will challenge in the to to have wet the numerous practice. to dosing. X be utilize. AMD can be months to to the new be of we CLS-AX dosed have a option Any market
treatment to patient patient. of from frequency The differ
eye varying a from of at Physicians for eye treatment same even accommodate and needs each fact, that might frequency will In to journey. eye patient, differ. flexibility to the times the the different of the patient in treatment schedule deliver need the the
Phase to from the to III evaluate refine our help trial data continue plans. ODYSSEY We
months. label of to Phase are on that X data We flexible will III a program between with dosing supportive designing produce focused X
mind easy development driven with III the practice, are most in will adoption keeping I the in our change. by subject mentioned, plans desired that physician AMD current and this in retinal remain to wet As Phase align enable and approach specialists
as currently are run We Phase X-milligram III to with trials planning X aflibercept comparator. a
trial Phase dosing We III dose a consistent with are to conduct flexible human study component, with in likely approved recently the design faricimab. the aflibercept high naive patients for and
Phase of present meeting conduct to with and our XXXX expect end in an the early plans. FDA II We finalize to
One reasons of suprachoroidal potential with I Clearside explore joined SCS delivery the Microinjector. the our to main for further was
to of formulation I translational have potentially our to utilize the I advancing deal great see my And new course many the molecules career, our Over and device expand a clinic. had platform in pipeline. into experience of opportunities
have in injection does that our we a vascular choroidal of retinal of change systemic in the is of suprachoroidal primarily endothelial enables in wet comprehensive small geographic via And significantly that. patient while well Therefore, also segment damaged ] in disease. as the choroid believe any and is hypothesis valued a the epithelium eye the disease over size academic with world of potentially minimizing targeting suprachoroidal $XX target occur choroid, choroid or ] is the coverage atrophy lower that The [ a colleagues my geographic retina billion are AMD. drug effects. side and significant both cells platform geographic delivery are anterior pigment Beyond preference for demonstrated the also market atrophy, even geographic before GA directly molecule atrophy supporting sales. density a well AMD, just RPE. the the with as choroidal in wet for important Delivering that at We disease. Several are atrophy, [
our report made that small have pleased I'm specific research potential evaluating GA. in in treatment the models molecule vivo to of for through certain great team progress
the We are for inflammatory perfusion, may X One and improve other currently may choroidal on moderate focused cells. approaches.
to doing [indiscernible] X new an advance Our team is work the potentially investigational toward drug necessary candidate application.
CLS-AX suprachoroidal CLS-AX results, Microinjector. what platform retinal in continue As treatment utilizing their I'm by of our and have drug our with This delivery delivery could impact excited positive George make innovative partners programs, future tremendous extensive suprachoroidal show a our for holds our combined described, SCS respective progress advancement, to the with suprachoroidal the that administration. diseases.
now that, With provide Deignan, financial to our Charlie update. a call the turn I'll CFO, to
